Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms

Abdelhamid, Mohamed Hadi Mohamed; Zayed, Ahmed S.; Ghoneima, Waleed; Elmarakbi, Akrm; Sheemy, Mohamed S. El; Aref, Ahmed; Abdelbary, Ahmed; Nour, Hani H.

doi:10.1007/s00345-016-1988-y

Cited by 13 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trospium chloride group had higher incidence of complications, especially constipation. 17 In contrast, Hekal et al showed that there was a lower incidence of LUTS in groups receiving solifenacin and trospium chloride (groups A and B) (P < .05), whereas dry mouth was significantly reported in group A. Individual comparisons with the placebo group (group D) showed a non-significant difference with those receiving antispasmodics (group C), whereas those receiving alpha blockers (group E) had a significant improvement in nocturia.…”

Section: Discussionmentioning

confidence: 91%

“…In contrast, another researcher seems to suggest that solifenacin is superior to tamsulosin, with the total USSQ being better for solifenacin, except for the sexual health index 20 . One study claims that solifenacin is superior to trospium chloride in controlling the symptoms attributed to pigtails, 17 whereas another study suggests that they are equal in all urinary domains of USSQ 18 …”

Section: Resultsmentioning

confidence: 99%

“…28 The SRS are similar to those of the overactive bladder (OAB) and are thought to be mediated by muscarinic receptors, after bladder mucosal irritation. 17 Others think that intramural ureter irritation is responsible for these symptoms. 25 Many studies have investigated the effect of various medications on SRS.…”

Section: Discussionmentioning

confidence: 99%

“…12 In contrast, another researcher seems to suggest that solifenacin is superior to tamsulosin, with the total USSQ being better for solifenacin, except for the sexual health index. 20 One study claims that solifenacin is superior to trospium chloride in controlling the symptoms attributed to pigtails, 17 whereas another study suggests that they are equal in all urinary domains of USSQ. 18 Some studies have explored the effects of a beta-3 agonist, namely mirabegron, on pigtail symptoms, where the patients that received mirabegron after pigtail insertion exhibited lower postoperative IPSS values and higher Overactive Bladder Questionnaire (OAB-q) values, compared with those who received a combination of tamsulosin and solifenacin, 16 whereas another study proves that mirabegron and tamsulosin have similar adequacy for the relief of SRS and that patients on mirabegron had lower analgesic requirements.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Ureteral Stent‐Related Symptoms and Pharmacotherapy: A Brief Narrative Review

Bellos,

Katsimperis,

Kapsalos‐Dedes

et al. 2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The purpose of this article is to review the effects of different types of pharmacotherapy on symptoms that affect the quality of a patient's life after stent insertion. A thorough Medline/PubMed nonsystematic review was conducted from 1987 to January 2023, using the terms: “pigtail” OR “ureteral stents” AND “lower urinary tracts symptoms” OR “LUTS” AND “pharmacotherapy” OR “drugs”. Relevant studies conducted in humans and reported in English language were included. The available reviews and articles associating the use of drugs with stent‐related symptoms (SRS) provide conflicting results. Most of them show a clear benefit of alpha blockers, particularly alfuzosin, on treating urinary SRS, and hence there is a strong recommendation for the use of alpha blockers for the treatment of SRS in the guidelines of the European Association of Urology. Anticholinergics and mirabegron have shown a significant benefit in dealing with irritative bladder symptoms. In contrast, the findings for combination therapies are contradictory, with some studies showing that combination therapy is no superior to monotherapy with regards to most of the subsets of the Ureteral Stent Symptom Questionnaire (USSQ), whereas others present a clear benefit of combination therapies, specifically silodosin and solifenacin, in treating stent‐associated lower urinary tract symptoms (LUTS), in comparison with any other type of monotherapy or combination therapy. Many studies suggest that some categories of pharmacotherapy, such as alpha blockers, can alleviate SRS. However, there is conflicting evidence concerning most other types of medical treatment. Randomized trials with the largest number of patients are needed to investigate the effectiveness of novel approaches on SRS.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Ureteral Stent‐Related Symptoms and Pharmacotherapy: A Brief Narrative Review

Bellos,

Katsimperis,

Kapsalos‐Dedes

et al. 2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…3 Many investigators have tried nonsteroidal anti-inflammatory analgesics, alpha blockers, M-receptor blockers, and other drugs to reduce the complication rate after ureteral stent placement, including the occurrence of postoperative ureteral fistula, and enhance patient comfort. [4][5][6][7] In addition, investigators continue to develop new biological materials for creating degradable ureteral stents that might also carry less risk of infection and facilitate the healing of ureteral injury. At present, these investigations are being carried out in preclinical in vivo experiments.…”

Section: Introductionmentioning

confidence: 99%

Effect of the Polaris Loop ureteral stent on vesicoureteral reflux and relief of lumbago symptoms: a single-center study

Yan

Qiao²,

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective To verify the effect of the Polaris Loop ureteral stent on vesicoureteral reflux and relief of lumbago symptoms in patients after ureteroscopic procedures. Methods This was a prospective single-center analysis of 20 patients who received indwelling bilateral ureteral stents after undergoing ureteroscopic lithotripsy. The Polaris Loop stent and Polaris Ultra stent (both F6 and 26 cm) were implanted randomly on the left and right sides of a patient. The results of the visual analogue scale (VAS) of the symptoms of lumbar discomfort that occurred within 2 weeks after surgery and whether or not vesicoureteral reflux occurred during postoperative cystography were recorded. Results The differences between the VAS scores and rates of vesicoureteral reflux for the 2 types of stents were significant (p<0.05). The patients receiving the Polaris Loop stent had lower VAS scores and lower rates of vesicoureteral reflux than the patients receiving the Polaris Ultra stent. Conclusions The Polaris Loop stent led to improved patient comfort after ureteroscopy and prevented vesicoureteral reflux of urine. However, careful selection of the appropriate length of stent and appropriate placement technique is required.

show abstract

Use of Drugs to Reduce the Morbidity of Ureteral Stents

et al. 2022

View full text Add to dashboard Cite

Double ureteral stents are amongst the commonest procedures performed in urology. However, there are complications such as infection, and encrustation associated with its use, together with uncomfortable lower urinary tract symptoms (LUTS). The latter are known as stent related symptoms (SRS) and are commonly reported in the scientific literature. SRS mentioned in literature are urgency, frequency, dysuria, haematuria, pain in the suprapubic and flank region. These can result in decreased sexual activity, reduced work performance, as well as decreased quality of life (QoL) in more than two-third of the patients. Drugs still hold the key in reducing the morbidity related to the ureteral stents.In terms of monotherapy, Alpha blockers as well as Antimuscarinics are effective in reducing SRS. Role of Mirabegron in the field is currently gaining importance. However, combination therapy reaches better outcomes than monotherapy alone while in cases with sexual dysfunction along with stent related symptoms, PDE5-I are better than other options. The role of complementary therapy for SRS with natural remedies is promising but needs to be assessed further. More randomized studies and laboratory trials are necessary to analyse possible alternative treatments for SRS that can heavily affects patients’ quality of life.

show abstract

Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms

Cited by 13 publications

References 29 publications

Ureteral Stent‐Related Symptoms and Pharmacotherapy: A Brief Narrative Review

Ureteral Stent‐Related Symptoms and Pharmacotherapy: A Brief Narrative Review

Effect of the Polaris Loop ureteral stent on vesicoureteral reflux and relief of lumbago symptoms: a single-center study

Use of Drugs to Reduce the Morbidity of Ureteral Stents

Contact Info

Product

Resources

About